

## TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
Corps Community Month Event Planning Form .....	300	1	300	.066	19.8
Corps Community Month Event Satisfaction .....	300	1	300	.033	9.9
Total .....	* 300	.....	* 300	.....	29.7

\* The same individuals complete both of the forms for a total of 300 respondents and responses.

**Jason E. Bennett,**

Director, Division of the Executive Secretariat.

[FR Doc. 2016–12146 Filed 5–23–16; 8:45 am]

BILLING CODE 4165–15-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Human Genome Research Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Human Genome Research Institute Special Emphasis Panel; Gabriella Miller Kids First Sequencing Center.

*Date:* June 14, 2016.

*Time:* 1:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* NHGRI, 5635FL, Twinbrook 4th Floor Conf. Rm., Twinbrook, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Rudy O. Pozzatti, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, 5635 Fishers Lane, Suite 4076, MSC 9306, Rockville, MD 20852, (301) 402–0838, [pozzatr@mail.nih.gov](mailto:pozzatr@mail.nih.gov).

*Name of Committee:* National Human Genome Research Institute Special Emphasis Panel; ENCODE MAPPING.

*Date:* June 21, 2016.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Washington Dulles Airport Marriott, 45020, Dulles View, Aviation Drive, Dulles, VA 20166.

*Contact Person:* Ken D. Nakamura, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 5635 Fishers Lane, Suite 4076, MSC 9306, Rockville, MD 20852, 301–402–0838, [nakamurk@mail.nih.gov](mailto:nakamurk@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS).

Dated: May 17, 2016.

**Sylvia L. Neal,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016–12139 Filed 5–23–16; 8:45 am]

BILLING CODE 4140–01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Prospective Grant of Exclusive Patent License: Development of Adeno-Associated Virus Vectors for the Treatment of Glycogen Storage Disease Type Ia**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license to practice the inventions embodied in the following Patent Applications to Dimension Therapeutics, Inc. (“Dimension”) located in Cambridge, Massachusetts, USA:

**Intellectual Property**

United States Provisional Patent Application No. 61/908,861, filed November 26, 2013, titled “Adeno-Associated Virus Vectors for the Treatment of Glycogen Storage Disease” [HHS Reference No. E–552–2013/0–US–01]; International Patent Application No. PCT/US2014/067415 filed November 25, 2014 titled “Adeno-Associated Virus Vectors for the

Treatment of Glycogen Storage Disease” [HHS Reference No. E–552–2013/0–PCT–02] and continuation applications, divisional applications and foreign counterpart applications claiming priority to the US provisional application No. 61/908,861.

With respect to persons who have an obligation to assign their right, title and interest to the Government of the United States of America, the patent rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive licensed territory may be worldwide and the field of use may be limited to:

“Development and commercialization of gene therapy using adeno-associated viral vectors for the treatment of Glycogen Storage Disease Type Ia.”

**DATES:** Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 8, 2016 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Surekha Vathyam, Ph.D., Senior Licensing and Patenting Manager, National Cancer Institute Technology Transfer Center, 9609 Medical Center Drive, Rm. 1E–530, MSC9702, Rockville, MD 20850–9702, Email: [vathyams@mail.nih.gov](mailto:vathyams@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** The subject technologies disclose novel adeno-associated virus (AAV) vectors expressing human glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC) for the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia). GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of G6Pase-alpha, a key enzyme in maintaining blood glucose homeostasis between meals. The two novel gene therapy vectors of the invention, rAAV-GPE-G6PC and rAAV-GPE-co-G6PC are recombinant AAV vectors expressing